| DRUG WATCH |
|
| Year : 2013 | Volume
: 45
| Issue : 5 | Page : 526-527 |
Anti B cell targeted therapy for autoimmune hemolytic anemia in an infant
Darshak Makadia1, Sirisha Rani Siddaiahgari1, MS Latha2
1 Department of Pediatrics and Pediatric Hemato Oncology, Rainbow Children's Tertiary Care Centre, Hyderabad, Andhra Pradesh, India
2 Department of Pharmacology, Hyderabad, Andhra Pradesh, India
Correspondence Address:
Sirisha Rani Siddaiahgari
Department of Pediatrics and Pediatric Hemato Oncology, Rainbow Children's Tertiary Care Centre, Hyderabad, Andhra Pradesh
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.117755
Autoimmune hemolytic anemia (AIHA) is an immune mediated destruction of erythrocytes, which has a good prognosis in children. It is known to have chronic, remitting or relapsing course, especially in infants and adolescents. Treatment of refractory or relapsing AIHA is a challenge as the other aim of the treatment is to avoid prolonged exposure to steroids or other immunosuppressants in small children. Rituximab is used in patients who are non-responsive to conventional treatment such as steroids, intravenous immunoglobulins and transfusion therapy. It has varying therapeutic success rate. We report a case of AIHA in a 4-month-old infant who had ill-sustained response to conventional therapy, but responded to rituximab.
[FULL TEXT] [PDF]*
|
